CA-OUTSEER
24.6.2021 15:03:06 CEST | Business Wire | Press release
Outseer has published its latest quarterly fraud and payments report, uncovering a significant spike in brand abuse attacks and a continued shift to more precise payment authentication methods. The Q2 installment of the report features insights from January through March of 2021 as captured through the Outseer Global Data Network, and collected while authenticating consumer transactions and investigating threats on behalf of Outseer customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624005352/en/
According to the report, Brand Abuse attacks impersonating companies through social media and published content now represents the majority of fraud attacks, growing from 27% in Q4 2020 to 68% in Q1 2021. This dramatic shift is attributed to the increased use of digital platforms including social media, web publishing, and cloud-based collaboration tools during the pandemic – all fertile hunting ground for fraudulent activity.
Phishing attacks designed to harvest user credentials represented 25% of all attack types for the quarter, followed by rogue mobile apps at 21%. Although the share of rogue mobile apps decreased slightly from the previous quarter, it is worth noting that this attack type increased by 14% in the same quarter vs. 2020. At just 7% of mix, Trojan Horse attacks injecting malware designed to harvest sensitive information and user credentials dropped again as threat actors have shifted fraud strategies to Brand Abuse.
“It comes as no surprise that fraud attack volume continues to grow at a record pace, considering the pronounced shift to digital commerce throughout the pandemic,” said Armen Najarian, Chief Marketing Officer of Outseer. “Global eCommerce spending grew 28% annually to $4.2 trillion in 2020, paving the way for more fraudulent behavior and more sophistication in attack types.”
Other notable insights from the Q2 Outseer Fraud & Payments Report include:
- Visibility into the more than 41,000 global cyber attacks
- Brand Abuse attacks volume share increased from the same time last year by 58% to 68% of all attacks in Q1 2021
- Phishing-based threats representing 25% of all attacks
- The U.S. accounts for 74% of all ISPs hosting phishing attacks
- The U.S was targeted by 16% of worldwide phishing attacks, with Canada at 22%
- The average value of fraudulent transaction in the web channel ($7,367) more than 2x the average value of a fraudulent transaction in the mobile channel ($3,368)
- Worldwide payment transaction volume authenticated with EMV 3-D Secure protocol grew by 59% year-over-year (Q1 2020 vs. Q1 2021)
- Worldwide payment transaction volume authenticated with the EMV 3-D Secure 2.0 protocol grew by 1667% year-over-year (Q1 2020 vs. Q1 2021)
Download the Q2 2021 report here: https://go.outseer.com/Fraud-Report-Q2.html
About Outseer
Outseer, an RSA Company, empowers the digital economy to grow by authenticating billions of transactions annually. Our payment and account monitoring solutions increase revenue and reduce customer friction for card issuing banks, payment processors, and merchants worldwide. Leveraging 20 billion annual transactions from 6,000 global institutions contributing to the Outseer Data Network, our identity-based science delivers the highest fraud detection rates and lowest customer intervention in the industry. See what others can’t at outseer.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005352/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
